SSTR2 and cancer: In GOT1 and BON1-SSTR2 cell lines, two neuroendocrine tumor models with different genetic backgrounds, this was accompanied by a sharp increase in cell death compared to both monotherapies, indicating that at least part of the reduction in viability can be attributed to cancer-eradicating cellular fates such as apoptosis.